2012 Breast Cancer Symposium Thursday

San Francisco, CA - Breast Cancer Symposium 2012: Mark D. Pegram, MD discusses Abstract #98 Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane
Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. during the General Session I: Controversial Topics in Medical Oncology Management at the Breast Cancer Symposium 2012 here today, Thursday September 13, 2012. The Symposium is supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology, ASBS American Society of Breast Surgeons and ASBC American Society of Breast Cancer. Over 1,000 physicians, researchers and allied healthcare professionals are attending the meeting which is being held at the San Francisco Marriott and features the latest Breast Cancer research in the areas of basic and clinical science. Photo by © ASCO/Todd Buchanan 2012 Technical Questions: todd@toddbuchanan.com;